Reviva Historical Balance Sheet

RVPH Stock

USD 1.77 0.01 0.56%

Trend analysis of Reviva Pharmaceuticals Holdings balance sheet accounts such as Other Assets of 467.6 K, Total Current Assets of 15.2 M, Common Stock of 3.4 K or Property Plant Equipment of 731 provides information on Reviva Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Reviva Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Reviva Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Reviva Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Reviva Pharmaceuticals is a good buy for the upcoming year.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Reviva Pharmaceuticals Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

About Reviva Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Reviva Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Reviva Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Reviva Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Reviva currently owns. An asset can also be divided into two categories, current and non-current.

Reviva Pharmaceuticals Balance Sheet Chart

As of now, Reviva Pharmaceuticals' Accounts Payable is increasing as compared to previous years. The Reviva Pharmaceuticals' current Other Assets is estimated to increase to about 467.6 K, while Retained Earnings are projected to decrease to (127 M).

Total Current Liabilities Accounts Payable Total Current Assets Capital Stock

Total Current Liabilities

Total Current Liabilities is an item on Reviva Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Reviva Pharmaceuticals Holdings are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Reviva Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Reviva Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Capital Stock

The total amount of a company's capital funded by shareholders through the issue and subscription of shares.

Most accounts from Reviva Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Reviva Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Reviva Pharmaceuticals Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

	2022	2024	2025 (projected)
Other Assets	403.8K	464.4K	467.6K
Accounts Payable	3.5M	4.4M	4.6M

Other Assets Accounts Payable

Reviva Pharmaceuticals balance sheet Correlations

	Other Current Liab	Total Current Liabilities	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Cash	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt
Other Current Liab		0.96	0.59	-0.92	0.85	0.3	0.62	0.91	-0.5	0.65	-0.79	0.37	-0.79	-0.65	0.66	-0.79	0.66	0.62	0.75	-0.79	-0.62	0.84	0.96	0.48	0.67	-0.79
Total Current Liabilities	0.96		0.41	-0.88	0.83	0.11	0.45	0.86	-0.37	0.49	-0.79	0.17	-0.79	-0.49	0.5	-0.79	0.5	0.46	0.69	-0.79	-0.5	0.8	1.0	0.29	0.51	-0.79
Net Tangible Assets	0.59	0.41		-0.74	0.77	0.76	0.95	0.81	-0.85	0.96	-0.45	0.94	-0.45	-0.98	0.96	-0.45	0.96	0.95	0.82	-0.45	-0.96	0.7	0.39	0.99	0.98	-0.45
Retained Earnings	-0.92	-0.88	-0.74		-0.97	-0.38	-0.75	-0.98	0.66	-0.78	0.67	-0.53	0.67	0.8	-0.79	0.67	-0.79	-0.76	-0.9	0.67	0.81	-0.9	-0.88	-0.66	-0.81	0.67
Accounts Payable	0.85	0.83	0.77	-0.97		0.34	0.74	0.98	-0.7	0.76	-0.7	0.55	-0.7	-0.79	0.77	-0.7	0.77	0.81	0.89	-0.7	-0.82	0.86	0.82	0.7	0.85	-0.7
Other Assets	0.3	0.11	0.76	-0.38	0.34		0.83	0.47	-0.57	0.83	-0.21	0.9	-0.21	-0.81	0.82	-0.21	0.82	0.62	0.59	-0.21	-0.78	0.45	0.11	0.79	0.63	-0.21
Total Current Assets	0.62	0.45	0.95	-0.75	0.74	0.83		0.8	-0.81	1.0	-0.36	0.91	-0.36	-0.98	1.0	-0.36	1.0	0.93	0.91	-0.36	-0.98	0.82	0.44	0.94	0.9	-0.36
Common Stock	0.91	0.86	0.81	-0.98	0.98	0.47	0.8		-0.7	0.83	-0.75	0.62	-0.75	-0.85	0.84	-0.75	0.84	0.82	0.91	-0.75	-0.86	0.89	0.85	0.73	0.87	-0.75
Property Plant Equipment	-0.5	-0.37	-0.85	0.66	-0.7	-0.57	-0.81	-0.7		-0.81	0.33	-0.76	0.33	0.82	-0.82	0.33	-0.82	-0.87	-0.74	0.33	0.82	-0.64	-0.34	-0.85	-0.86	0.33
Total Assets	0.65	0.49	0.96	-0.78	0.76	0.83	1.0	0.83	-0.81		-0.42	0.91	-0.42	-0.99	1.0	-0.42	1.0	0.93	0.91	-0.42	-0.98	0.82	0.47	0.94	0.92	-0.42
Short Long Term Debt Total	-0.79	-0.79	-0.45	0.67	-0.7	-0.21	-0.36	-0.75	0.33	-0.42		-0.31	1.0	0.47	-0.42	1.0	-0.42	-0.41	-0.44	1.0	0.42	-0.48	-0.78	-0.36	-0.55	1.0
Total Stockholder Equity	0.37	0.17	0.94	-0.53	0.55	0.9	0.91	0.62	-0.76	0.91	-0.31		-0.31	-0.93	0.9	-0.31	0.9	0.83	0.68	-0.31	-0.89	0.51	0.15	0.97	0.86	-0.31
Current Deferred Revenue	-0.79	-0.79	-0.45	0.67	-0.7	-0.21	-0.36	-0.75	0.33	-0.42	1.0	-0.31		0.47	-0.42	1.0	-0.42	-0.41	-0.44	1.0	0.42	-0.48	-0.78	-0.36	-0.55	1.0
Net Debt	-0.65	-0.49	-0.98	0.8	-0.79	-0.81	-0.98	-0.85	0.82	-0.99	0.47	-0.93	0.47		-0.99	0.47	-0.99	-0.92	-0.88	0.47	0.98	-0.76	-0.48	-0.96	-0.95	0.47
Cash	0.66	0.5	0.96	-0.79	0.77	0.82	1.0	0.84	-0.82	1.0	-0.42	0.9	-0.42	-0.99		-0.42	1.0	0.93	0.92	-0.42	-0.98	0.83	0.49	0.94	0.92	-0.42
Non Currrent Assets Other	-0.79	-0.79	-0.45	0.67	-0.7	-0.21	-0.36	-0.75	0.33	-0.42	1.0	-0.31	1.0	0.47	-0.42		-0.42	-0.41	-0.44	1.0	0.42	-0.48	-0.78	-0.36	-0.55	1.0
Cash And Short Term Investments	0.66	0.5	0.96	-0.79	0.77	0.82	1.0	0.84	-0.82	1.0	-0.42	0.9	-0.42	-0.99	1.0	-0.42		0.93	0.92	-0.42	-0.98	0.83	0.49	0.94	0.92	-0.42
Common Stock Total Equity	0.62	0.46	0.95	-0.76	0.81	0.62	0.93	0.82	-0.87	0.93	-0.41	0.83	-0.41	-0.92	0.93	-0.41	0.93		0.87	-0.41	-0.92	0.79	0.44	0.94	0.96	-0.41
Common Stock Shares Outstanding	0.75	0.69	0.82	-0.9	0.89	0.59	0.91	0.91	-0.74	0.91	-0.44	0.68	-0.44	-0.88	0.92	-0.44	0.92	0.87		-0.44	-0.93	0.96	0.68	0.78	0.83	-0.44
Short Term Investments	-0.79	-0.79	-0.45	0.67	-0.7	-0.21	-0.36	-0.75	0.33	-0.42	1.0	-0.31	1.0	0.47	-0.42	1.0	-0.42	-0.41	-0.44		0.42	-0.48	-0.78	-0.36	-0.55	1.0
Non Current Liabilities Total	-0.62	-0.5	-0.96	0.81	-0.82	-0.78	-0.98	-0.86	0.82	-0.98	0.42	-0.89	0.42	0.98	-0.98	0.42	-0.98	-0.92	-0.93	0.42		-0.81	-0.49	-0.94	-0.93	0.42
Other Stockholder Equity	0.84	0.8	0.7	-0.9	0.86	0.45	0.82	0.89	-0.64	0.82	-0.48	0.51	-0.48	-0.76	0.83	-0.48	0.83	0.79	0.96	-0.48	-0.81		0.8	0.63	0.73	-0.48
Total Liab	0.96	1.0	0.39	-0.88	0.82	0.11	0.44	0.85	-0.34	0.47	-0.78	0.15	-0.78	-0.48	0.49	-0.78	0.49	0.44	0.68	-0.78	-0.49	0.8		0.28	0.49	-0.78
Net Invested Capital	0.48	0.29	0.99	-0.66	0.7	0.79	0.94	0.73	-0.85	0.94	-0.36	0.97	-0.36	-0.96	0.94	-0.36	0.94	0.94	0.78	-0.36	-0.94	0.63	0.28		0.96	-0.36
Property Plant And Equipment Gross	0.67	0.51	0.98	-0.81	0.85	0.63	0.9	0.87	-0.86	0.92	-0.55	0.86	-0.55	-0.95	0.92	-0.55	0.92	0.96	0.83	-0.55	-0.93	0.73	0.49	0.96		-0.55
Short Long Term Debt	-0.79	-0.79	-0.45	0.67	-0.7	-0.21	-0.36	-0.75	0.33	-0.42	1.0	-0.31	1.0	0.47	-0.42	1.0	-0.42	-0.41	-0.44	1.0	0.42	-0.48	-0.78	-0.36	-0.55

Click cells to compare fundamentals

Reviva Pharmaceuticals Account Relationship Matchups

Reviva Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Other Current Liab	(683.3K)	1.3M	(1.0M)	13.3M	15.3M	16.1M
Total Current Liabilities	1.3M	2.3M	6.0M	17.2M	19.8M	20.7M
Net Tangible Assets	(35.9M)	7.4M	28.7M	12.3M	14.2M	14.9M
Retained Earnings	(58.3M)	(66.8M)	(91.2M)	(134.4M)	(120.9M)	(127.0M)
Accounts Payable	1.0M	509.6K	3.5M	3.8M	4.4M	4.6M
Total Current Assets	8.8M	31.4M	18.9M	23.7M	27.3M	15.2M
Common Stock	923.0	1.4K	2.0K	2.8K	3.2K	3.4K
Total Assets	8.8M	31.4M	18.9M	23.7M	27.3M	18.2M
Total Stockholder Equity	7.4M	28.7M	12.3M	5.7M	6.6M	10.4M
Net Debt	(8.8M)	(29.7M)	(18.5M)	(23.4M)	(21.0M)	(22.1M)
Cash	8.8M	29.7M	18.5M	23.4M	26.9M	17.7M
Cash And Short Term Investments	8.8M	29.7M	18.5M	23.4M	26.9M	17.7M
Common Stock Shares Outstanding	3.1M	14.8M	19.5M	23.8M	27.4M	14.1M
Liabilities And Stockholders Equity	8.8M	31.4M	18.9M	23.7M	27.3M	18.2M
Non Current Liabilities Total	3.0M	372.7K	567.4K	806.7K	726.0K	1.4M
Other Stockholder Equity	65.7M	95.5M	103.5M	140.1M	161.1M	105.2M
Total Liab	1.3M	2.7M	6.6M	18.0M	20.7M	21.7M
Net Invested Capital	7.4M	28.7M	12.3M	5.7M	6.6M	4.8M
Capital Stock	923.0	1.4K	2.0K	2.8K	2.5K	2.4K
Net Working Capital	7.4M	29.1M	12.9M	6.5M	7.5M	10.8M

Currently Active Assets on Macroaxis

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin
ADA	Cardano
XRP	XRP

When determining whether Reviva Pharmaceuticals is a strong investment it is important to analyze Reviva Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Reviva Pharmaceuticals' future performance. For an informed investment choice regarding Reviva Stock, refer to the following important reports:

How To Invest In Reviva

Details

Is Reviva Stock a good investment?

Details

What is Reviva Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reviva Pharmaceuticals. If investors know Reviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.07)

Return On Assets

(2.34)

Return On Equity

(17.95)

The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Reviva Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reviva Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reviva Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Reviva Historical Balance Sheet

About Reviva Balance Sheet Analysis

Reviva Pharmaceuticals Balance Sheet Chart

Total Current Liabilities

Accounts Payable

Total Current Assets

Capital Stock

Reviva Pharmaceuticals balance sheet Correlations

Reviva Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Reviva Pharmaceuticals balance sheet Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Current Liabilities
Total Assets	+ 1.0	Total Current Assets
Cash	+ 1.0	Total Current Assets
Cash And Short Term Investments	+ 1.0	Total Current Assets
Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets

Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Net Debt	- 0.99	Total Assets
Non Current Liabilities Total	- 0.98	Cash And Short Term Investments
Non Current Liabilities Total	- 0.98	Cash
Non Current Liabilities Total	- 0.98	Total Assets